The Bextra Effect: No Relief for Biotechs

April 2005
Investment Dealers' Digest;4/18/2005, Vol. 71 Issue 15, p14
Trade Publication
The article reports on certain developments in the pharmaceutical industry. Pfizer Inc. has announced that it is pulling Bextra off the market. With Big Pharma stock prices hurting, specialty drug and biotechnology companies hoping to hit the initial public offering market are also feeling the pain. The Bextra news comes on the heels of the decision by Biogen Idee Inc. and Elan Corp. to pull Tysabri off the market after it was linked to one death. A bunch of money has been lost on the buy side because of the Biogens and Elans of the world, and certainly investors have taken a more subdued approach to the group.


Related Articles

  • Pharmaceutical Company Round-up.  // PharmaWatch: Monthly Review;May2005, Vol. 4 Issue 5, p3 

    The article reports on the issues surrounding developments in the pharmaceutical industry in the U.S. Biogen Idec and Elan are facing issues of drug safety after a patient died and another developed progressive multifocal leukoencephalopathy when taking Biogen Idec drug, Avonex. Pfizer has...

  • Elan/Biogen Idec: Antegren offers renewed hope for growth.  // PharmaWatch: Biotechnology;March 2004, Vol. 3 Issue 3, p4 

    Reports on the success of the Phase III maintenance trial of Antegren in Crohn's disease by Elan Corp. PLC; and Biogen Idec. Increase of the share price of Elan; Effectiveness of the product in preventing patients from relapsing once the disease is in remission; Probability of marketing the...

  • Drug stocks are out of favor-so snap up the bargains. Hauke, Keenan // Indianapolis Business Journal;12/11/2006, Vol. 27 Issue 40, p29 

    The author discusses the negative sentiments surrounding the health care stock and its need to adopt to changes in light of recent developments in the stock market in Indianapolis, Indiana. He cites the recent changes adopted by Pfizer Inc. as the company readies for a more challenging market...

  • EMEA Finds More Tysabri PMLs; Squeezes Key Market Overseas. Boggs, Jennifer // BioWorld Today;10/26/2009, Vol. 20 Issue 206, p1 

    The article reports that share prices of Biogen Idec Inc. and its partner Elan Corp. PLC declined when it was revealed that there were higher cases of progressive multifocal leukoencephalopathy (PML) associated with the multiple sclerosis drug Tysabri than previously reported. The new cases,...

  • TOP STORIES.  // MondayMorning;8/4/2008, Vol. 16 Issue 30, p1 

    The article presents information on various issues related to several companies. Share prices of Biogen Inc. and Elan Corp. PLC fell after there were two new cases of a deadly brain infection in patients taking Tysabri, a multiple sclerosis drug produced by the companies in the U.S. Andrew...

  • CNS News Round-Up.  // PharmaWatch: CNS;January 2005, Vol. 4 Issue 1, p2 

    Reports developments in the pharmaceutical industry. Decline in the stock price of Biovail Corp.; Market withdrawal of Celebrex drug by Pfizer Inc. in Turkey; Acceptance of the supplemental new drug application of Forest Laboratories Inc. by the U.S. Food and Drug Administration.

  • Elan Drug Technologies.  // Contract Pharma;2010 Directory, Vol. 11 Issue 10, p93 

    The article profiles Elan Drug Technologies Ltd., a drug development and manufacturing company with offices in Ireland and the U.S. It is said that the company started in 1969 and has about 700 employees. It is noted that the company offers several services including technology transfer, drug...

  • Latelines.  // Drug Topics;11/19/2001, Vol. 145 Issue 22, p5 

    Presents news briefs on the pharmaceutical industry as of November 19, 2001. Information on Frova drug from Elan Corp.; Details on anthrax guidelines issued by the American College of Obstetricians and Gynecologists; Warning to patients who are taking warfarin and cancer drug Xeloda.

  • Elan: easing pain in the EU.  // PharmaWatch: Monthly Review;Apr2005, Vol. 4 Issue 4, p16 

    The article reports on the approval issued by the European Commission to Elan Corp. PLC for its Prialt, an intrathecal chronic pain drug. It has indicated that Prialt provide an effective and safe treatment for patients for whom other treatment has failed. Prialt is a non-opioid, neuron-specific...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics